One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
The Platinum Hall of Fame
doi : 10.1016/j.eururo.2024.01.009
Volume 85, Issue 3, March 2024, Pages e65-e75
The Intersection of Artificial Intelligence and Social Media in Shaping the New Digital Health Frontier: Powers and Perils
Nikita R. Bhatt a,*, Esther Garc?´a Rojo b , Vineet Gauhar c , Claudia Mercader d , Vito Cucchiara e,f,g , Carla Bezuidenhout h , Marc van Gurp i , Jarka Bloemberg i , Jeremy Yuen-Chun Teoh j , Maria J. Ribal d , Gianluca Giannarini k , on behalf of the European Association of Urology Guidelines Office Dissemination Committee
doi : 10.1016/j.eururo.2023.11.025
Volume 85, Issue 3, March 2024, Pages 183-184
Robot-assisted Radical Prostatectomy with the Dexter Robotic System: Initial Experience and Insights into On-demand Robotics
Damien Thillou *, Humphrey Robin, Coline Ricolleau, Nadia Ali Benali, Aure´lien Forgues, Damien Emeriau, Hubert Mignot, Guillaume Hugues
doi : 10.1016/j.eururo.2023.05.034
Volume 85, Issue 3, March 2024, Pages 185-189
Opening up the Market to New Robotic Platforms: The Best Way To Handle New Options
Nicola Frego a,b,c,y, Claudia Colla` Ruvolo a,b,d,y, Alexandre Mottrie
doi : 10.1016/j.eururo.2023.06.015
Volume 85, Issue 3, March 2024, Pages 190-192
Prostate-Specific Membrane Antigen–Targeted Therapies for Prostate Cancer: Towards Improving Therapeutic Outcomes
Matteo Corpetti a,b , Cristina Mu¨ller c,d , Himisha Beltran e,f , Johann de Bono g,h , Jean-Philippe Theurillat
doi : 10.1016/j.eururo.2023.11.018
Volume 85, Issue 3, March 2024, Pages 193-204
Prostate-specific Membrane Antigen–targeted Isotope Therapy: Inherent Challenges Owing to Heterogeneity and Clonal Evolution
Oliver Sartor
doi : 10.1016/j.eururo.2023.12.008
Volume 85, Issue 3, March 2024, Pages 205-206
Population-based Organised Prostate Cancer Testing: Results from the First Invitation of 50-year-old Men
Ola Bratt a,b,*, Rebecka Arnsrud Godtman a,b,y, Thomas Jiborn c , Jonas Wallstro¨m d,e , Olof Akre f,g , Stefan Carlsson f,g , Tobias Nordstro¨m h , Erik Thimansson i,j , Max Alterbeck c,i , Sophia Zackrisson i,k , Jonas Hugosson a,b , Anders Bjartell c,i,y, Anna Lantz
doi : 10.1016/j.eururo.2023.11.013
Volume 85, Issue 3, March 2024, Pages 207-214
Prostate Cancer Screening at its Best: The Swedish Organized Prostate Cancer Testing Program
Peter Albers a,b,*, Hendrik van Poppel
doi : 10.1016/j.eururo.2023.11.026
Volume 85, Issue 3, March 2024, Pages 215-216
Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study
Renu S. Eapen a,b,c,*, James P. Buteau b,c,d , Price Jackson c,e , Catherine Mitchell f , Sheng F. Oon g , Omar Alghazo a , Lachlan McIntosh d , Nattakorn Dhiantravan d , Mark J. Scalzo b,d , Jonathan O’Brien a , Shahneen Sandhu c,h , Arun A. Azad c,h , Scott G. Williams c,i , Gaurav Sharma b , Mohammad B. Haskali j , Mathias Bressel c,k , Kenneth Chen a , Pocharapong Jenjitranant a , Aoife McVey a,b , Daniel Moon a , Nathan Lawrentschuk a , Paul J. Neeson c,l , Declan G. Murphy a,b,c,y, Michael S. Hofman
doi : 10.1016/j.eururo.2023.08.026
Volume 85, Issue 3, March 2024, Pages 217-226
A New Chapter in Neoadjuvant Therapy for High-risk Prostate Cancer?
Ulrich Krafft a,b,*, Boris A. Hadaschik a,b , Katharina Lu¨ckerath b,c , Ken Herrmann
doi : 10.1016/j.eururo.2023.09.022
Volume 85, Issue 3, March 2024, Pages 227-228
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial
Nobuaki Matsubara a , Ronald de Wit b , Arjun Vasant Balar c,y, Arlene O. Siefker-Radtke d , Jakub Zolnierek e , Tibor Csoszi f , Sang Joon Shin g , Se Hoon Park h , Vagif Atduev i , Mahmut Gumus j , Yu-Li Su k , Saziye Burcak Karaca l , Herna´n Javier Cutuli m , Mehmet A.N. Sendur n , Liji Shen o , Karen O’Hara p , Chinyere E. Okpara p , Sonia Franco o , Blanca Homet Moreno o , Petros Grivas q,*, Yohann Loriot
doi : 10.1016/j.eururo.2023.08.012
Volume 85, Issue 3, March 2024, Pages 229-238
LEAP-011 in Urothelial Cancer. Unraveling the Puzzle: Combination or Cohort?
Shilpa Gupta a,*, Andrea Necchi
doi : 10.1016/j.eururo.2023.11.010
Volume 85, Issue 3, March 2024, Pages 239-241
Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer
Wolfgang Beckabir a,b , Sara E. Wobker a,c , Jeffrey S. Damrauer a,d , Bentley Midkiff a , Gabriela De la Cruz a , Vladmir Makarov e , Leah Flick a , Mark G. Woodcock a,b , Petros Grivas f , Marc A. Bjurlin a,g , Michael R. Harrison h , Benjamin G. Vincent a,b,i,j,k , Tracy L. Rose a,d , Shilpa Gupta e , William Y. Kim a,d,l,m,y,*, Matthew I. Milowsky
doi : 10.1016/j.eururo.2023.11.008
Volume 85, Issue 3, March 2024, Pages 242-253
Predicting Response in TIME and Space: Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer
Priyanka Yolmo a,b , D. Robert Siemens a,b,c , Madhuri Koti
doi : 10.1016/j.eururo.2023.12.003
Volume 85, Issue 3, March 2024, Pages 254-256
Management of Lymph Node–positive Penile Cancer: A Systematic Review
Ashwin Sachdeva a,b,* ,y, Luke McGuinness c,y, ?ukasz Zapala d , Isabella Greco e , Herney Andres Garcia-Perdomo f , Mithun Kailavasan g , Tiago Antunes-Lopes h , Benjamin Ayres i , Lenka Barreto j , Riccardo Campi k , Juanita Crook l , Peter Johnstone m , Vivek Kumar n , Kenneth Manzie o , Jack David Marcus p , Andrea Necchi q , Pedro Oliveira r,s,t , John Osborne o , Lance C. Pagliaro u , Chris Protzel v , R. Bryan Rumble w , Diego F. Sa´nchez Mart?´nez x , Philippe E. Spiess y , Scott T. Tagawa z , Michiel S. van der Heijden aa , Arie S. Parnham b , Curtis A. Pettaway bb , Maarten Albersen cc , Vijay K. Sangar a,b , Oscar R. Brouwer dd,à , Vasileios I. Sakalis
doi : 10.1016/j.eururo.2023.04.018
Volume 85, Issue 3, March 2024, Pages 257-273
A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA
Emeline Colomba a,*,y, Sarah Flora Jonas b,y, Jean-Christophe Eymard c , Re´mi Delva d , Pierre Emmanuel Brachet e , Yann Neuzillet f , Nicolas Penel g,h , Guilhem Roubaud i , Emmanuelle Bompas j , Hakim Mahammedi k , Raffaelle Longo l , Carole Helissey m , Philippe Barthe´lemy n , Delphine Borchiellini o , Ali Hasbini p , Franck Priou q , Carolina Saldana r , Eric Voog s , Be´range`re Narcisso t , Sylvain Ladoire u , Jean-Franc¸ ois Berdah v , Jean-Baptiste Aisenfarb w , Ste´phanie Foulon b , Karim Fizazi
doi : 10.1016/j.eururo.2023.05.009
Volume 85, Issue 3, March 2024, Pages 274-282
Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non–organ-confined Upper Tract Urothelial Carcinoma
Heather L. Huelster a , Billie Gould b , Elizabeth A. Schiftan a , Lucia Camperlengo a , Facundo Davaro a , Kyle M. Rose a , Alex C. Soupir c , Shidong Jia b , Tiantian Zheng b , Wade J. Sexton a , Julio Pow-Sang a , Philippe E. Spiess a , G. Daniel Grass d , Liang Wang c , Xuefeng Wang e , Aram Vosoughi f , Andrea Necchi g , Joshua J. Meeks h , Bishoy M. Faltas i , Pan Du b , Roger Li a,*
doi : 10.1016/j.eururo.2023.09.017
Volume 85, Issue 3, March 2024, Pages 283-292
Assessing Long-term Treatment Benefits Using Complementary Statistical Approaches: An In Silico Analysis of the Phase III Keynote-045 and Checkmate-214 Immune Checkpoint Inhibitor Trials
Ana Cavillon a , Damien Pouessel b , Nadine Houe´de´ c , Fanny Mathevet a , Jean Yves Dauxois d , Christine Chevreau b , Ste´phane Culine e,f , Jean-Pierre Delord b , Raphael Porcher g,h , Thomas Filleron
doi : 10.1016/j.eururo.2023.02.011
Volume 85, Issue 3, March 2024, Pages 293-300
Re: Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancera
doi : 10.1016/j.eururo.2023.10.002
Volume 85, Issue 3, March 2024, Pages 301-302
Re: Unilateral Pelvic Lymph Node Dissection in Prostate Cancer Patients Diagnosed in the Era of Magnetic Resonance Imaging-targeted Biopsy: A Study that Challenges the Dogma
Gabriele Sorce a,b,c,* Alexandre Mottrie
doi : 10.1016/j.eururo.2023.10.001
Volume 85, Issue 3, March 2024, Page 302
Re: Which Patients with Metastatic Hormone-sensitive Prostate Cancer Benefit from Docetaxel: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Trials
Daniele Raggi a Antonio Cigliola b,* Chiara Mercinelli b Damiano Patanè a Valentina Tateo b Carlo Bosi b Emanuele Crupi b Giorgio Gandaglia a Alberto Briganti b Andrea Necchi
doi : 10.1016/j.eururo.2023.11.007
Volume 85, Issue 3, March 2024, Page 303
Re: Chimeric Antigen Receptor T Cells as Adjuvant Therapy for Unresectable Adenocarcinoma
Rodrigo Espa?a-Navarro a,* Karim Touijer
doi : 10.1016/j.eururo.2023.10.017
Volume 85, Issue 3, March 2024, Page 304
Re: Grade V Renal Trauma Management: Results from the Multi-institutional Genito-urinary Trauma Study
Alvaro Yebes * Luis Martinez-Pi?eiro
doi : 10.1016/j.eururo.2023.11.001
Volume 85, Issue 3, March 2024, Page 305
Re: Pembrolizumab Versus Placebo as Post-nephrectomy Adjuvant Therapy for Clear Cell Renal Cell Carcinoma (KEYNOTE-564): 30-month Follow-up Analysis of a Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Trial
Carlos Toribio-V?zquez a,b,* Luis Martinez-Pi?eiro
doi : 10.1016/j.eururo.2023.10.019
Volume 85, Issue 3, March 2024, Page 306
Antimicrobial Resistance Patterns in Children with Continuous Antibiotic Prophylaxis: A Meta-analysis of Randomised Controlled Trials
Ophelia Aubert a,*, Martin Lacher a , Jens-Uwe Stolzenburg b , Caela´n Max Haney
doi : 10.1016/j.eururo.2023.12.002
Volume 85, Issue 3, March 2024, Pages 307-308
Reply to Arnulf Stenzl, Morgan Rouprêt, J. Alfred Witjes, Paolo Gontero. High-quality Transurethral Resection of Bladder Tumour Needs Additional Forms of Tumour Delineation. Eur Urol 2023;83:193–4
Rakesh Heer a,*, Wei Shen Tan b , Paul Gravestock c , Thenmalar Vadiveloo d , Rebecca Lewis e , Steven Penegar e , Luke Vale f , Graeme MacLennan d , Emma Hall e , on behalf of the PHOTO Trial Team
doi : 10.1016/j.eururo.2023.05.040
Volume 85, Issue 3, March 2024, Pages 309-312
Reply to Badar M. Mian. Prostate Biopsy: Hyperbole and Misrepresentation Versus Scientific Evidence and Equipoise. Eur Urol. 2024;85:99–100
Adrian Pilatz a,*, Steven MacLennan b , Roderick C.N. van den Bergh c , Rajan Veeratterapillay d , Muhammad Imran Omar e , Yuhong Yuan f , Phillip Cornford g , Gernot Bonkat
doi : 10.1016/j.eururo.2023.09.008
Volume 85, Issue 3, March 2024, Pages 313-314
Re: Giuseppe Basile, Giuseppe Fallara, Paolo Verri, et al. The Role of 99mTc-Sestamibi Single-photon Emission Computed Tomography/Computed Tomography in the Diagnostic Pathway for Renal Masses: A Systematic Review and Meta-analysis. Eur Urol. 2024;85:63–71
Giovanni Lughezzani a,b,* Paolo Casale b Laura Evangelista
doi : 10.1016/j.eururo.2023.11.020
Volume 85, Issue 3, March 2024, Page e76
Reply to Giovanni Lughezzani, Paolo Casale, and Laura Evangelista’s Letter to the Editor re: Giuseppe Basile, Giuseppe Fallara, Paolo Verri, et al. The Role of 99mTc-Sestamibi Single-photon Emission Computed Tomography/Computed Tomography in the Diagnostic Pathway for Renal Masses: A Systematic Review and Meta-analysis. Eur Urol. 2024;85:63–71
Giuseppe Basile a,b,* Andrea Gallioli b Arturo Chiti c Umberto Capitanio a Alberto Breda
doi : 10.1016/j.eururo.2023.11.021
Volume 85, Issue 3, March 2024, Pages e77-e78
Re: William Morello, Esra Baskin, Augustina Jankauskiene, et al. Antibiotic Prophylaxis in Infants with Grade III, IV, or V Vesicoureteral Reflux. N Engl J Med 2023;389:987–97
Andrew T. Gabrielson Logan Galansky Heather N. Di Carlo
doi : 10.1016/j.eururo.2023.10.025
Volume 85, Issue 3, March 2024, Pages e79-e80
Reply to Andrew T. Gabrielson, Logan Galansky, and Heather N. Di Carlo’s Letter to the Editor re: William Morello, Esra Baskin, Augustina Jankauskiene, et al. Antibiotic Prophylaxis in Infants with Grade III, IV, or V Vesicoureteral Reflux. N Engl J Med 2023;389:987–97
William Morello a Giuseppe Puccio a Emanuele Proverbio a Giovanni Montini
doi : 10.1016/j.eururo.2023.11.024
Volume 85, Issue 3, March 2024, Pages e81-e82
Re: Michael Eppler, Conner Ganjavi, Lorenzo Storino Ramacciotti, et al. Awareness and Use of ChatGPT and Large Language Models: A Prospective Cross-sectional Global Survey in Urology. Eur Urol. 2024;85:146–53
Zhongwei Zhao a,y Zhenye Li b,y Nengwang Yu
doi : 10.1016/j.eururo.2023.12.006
Volume 85, Issue 3, March 2024, Pages e83-e84
Reply to Rui-Cheng Wu, Deng-Xiong Li, and De-Chao Feng’s Letter to the Editor re: Michael Eppler, Conner Ganjavi, Lorenzo Storino Ramacciotti, et al. Awareness and Use of ChatGPT and Large Language Models: A Prospective Cross-sectional Global Survey in Urology. Eur Urol. 2024;85:146–53.
Michael Eppler a,b Conner Ganjavi a,b Andre Abreu a,b Inderbir Gill a,b Giovanni E. Cacciamani
doi : 10.1016/j.eururo.2023.12.007
Volume 85, Issue 3, March 2024, Pages e85-e86
Re: Michael Eppler, Conner Ganjavi, Lorenzo Storino Ramacciotti, et al. Awareness and Use of ChatGPT and Large Language Models: A Prospective Cross-sectional Global Survey in Urology. Eur Urol. 2024;85:146–53.
Rui-Cheng Wu y Deng-Xiong Li y De-Chao Feng
doi : 10.1016/j.eururo.2023.11.029
Volume 85, Issue 3, March 2024, Pages e87-e88
Re: Laura Bukavina, Amy N. Luckenbaugh, Michael S. Hofman, et al. Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer. Eur Urol 2022;83:521–33
Giorgio Gandaglia a,b Francesco Barletta a,b,* Alberto Briganti a,b Francesco Montorsi
doi : 10.1016/j.eururo.2023.09.015
Volume 85, Issue 3, March 2024, Page e89
Re: Martha Boone. The Unfettered Urologist. What I Never Had Time to Tell You in a Fifteen Minute Office Visit. New York, NY: Morgan James Publishing; 2023
Rodolfo Montironi a,* Liang Cheng b Alessia Cimadamore c Antonio Lopez-Beltran
doi : 10.1016/j.eururo.2023.10.021
Volume 85, Issue 3, March 2024, Pages e90-e91
Lasers and Stones: Towards an Approach that Depends on the Stone Type? A Point of View from PEARLS Members
Frédéric Panthier a,b,c,f,* Eugenio Ventimiglia b,d,e Olivier Traxer a,b,c,f Mariela Corrales a,b,d,f Etienne Xavier Keller
doi : 10.1016/j.eururo.2023.10.023
Volume 85, Issue 3, March 2024, Pages e92-e93
Re: Robert J. Motzer, Pratik P. Rane, Todd L. Saretsky, et al. Patient-reported Outcome Measurement and Reporting for Patients with Advanced Renal Cell Carcinoma: A Systematic Literature Review. Eur Urol. Eur Urol. 2023;84:406–17
Andrés Felipe Gutiérrez Rojas a,* Daniel Fern?ndez b Cesar Diaz Ritter
doi : 10.1016/j.eururo.2023.08.032
Volume 85, Issue 3, March 2024, Page e94
Corrigendum to “Effect of Peritoneal Fixation (PerFix) on Lymphocele Formation in Robot-assisted Radical Prostatectomy with Pelvic Lymphadenectomy: Results of a Randomized Prospective Trial� [Eur. Urol. 83(2) (2023) 154–162]
Vladimir Student Jr. a,d,*, Zbynek Tudos b , Zuzana Studentova a , Ondrej Cesak a , Hana Studentova c , Vaclav Repa d , Dana Purova d , Vladimir Student
doi : 10.1016/j.eururo.2023.12.012
Volume 85, Issue 3, March 2024, Page e95
Corrigendum to “Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score� [Eur. Urol. 83(5) (2024) 432–440]
Matthew D. Galsky a,*, Dean F. Bajorin b , Johannes Alfred Witjes c , Ju¨rgen E. Gschwend d , Yoshihiko Tomita e , Federico Nasroulah f , Jun Li f , Sandra Collette g , Begon?a P. Valderrama h , Marc-Oliver Grimm i , Leonard Appleman j , Gwenaelle Gravis k , Andrea Necchi l,y, Dingwei Ye m , Frank Stenner n , Megan Wind-Rotolo f,à , Joshua Zhang f , Keziban U¨nsal-Kac¸ maz f,§
doi : 10.1016/j.eururo.2023.12.013
Volume 85, Issue 3, March 2024, Pages e96-e97
